Johnson & Johnson Presents New Data on ACUVUE® OASYS MAX 1-Day Contact Lenses at #Academy24
- Research highlights the OptiBlue™ Light Filter which provides 60% blue-violet light filteringŦ and a handling tint that helps during contact lens insertion
- Attendees can learn about the Eye-Inspired Design™ of ACUVUE® contact lenses designed to work in harmony with the natural physiology and anatomy of the eye1
JACKSONVILLE, FL, November 4, 2024 – Johnson & Johnson*, a global leader in eye health, will present data on the ACUVUE® OASYS MAX 1-Day family of contact lenses including contrast sensitivity, brightness of natural images, lens handling, and more. Data will also be presented on myopia management, use of digital technologies like machine learning to identify potential eye disease, and fresh insights on health economics and market access. In addition, a session on Eye-Inspired Design™ from ACUVUE® provides information about where technology and comfort intersect+ to help meet patient contact lens needs.
“Research and scientific data are fundamental to the eye health innovations we bring to patients,” said Dr. Xiao-Yu Song, Global Head of R&D, Vision, Johnson & Johnson.‡ “We are excited to share our latest findings within 23 accepted abstracts that uncover ways we can improve visual outcomes for patients through technology and real world evidence.”
Data Highlights Presented at Academy 2024
Appearance and Handling Benefit of ACUVUE® OASYS MAX 1-Day Family of Lenses
Meredith Bishop et al.
Contact lens handling, specifically insertion, can be a challenge for wearers of all ages. A consumer study of 98 habitual contact lens wearers found that the unique blue-green appearance of ACUVUE® OASYS MAX 1-Day made the lens easier to see in the blister package and allowed for superior handling when compared to Dailies Total1®. This is particularly meaningful to presbyopia patients, where seeing the lens up close is a challenge. ACUVUE® OASYS MAX 1-Day’s unique blue-green appearance is a result of the combination of the OptiBlue™ Technology blue-violet light filter and a blue handling tint.
Evaluating the impact of an HEV-filtering multifocal contact lens on halos and light scatter
Randy and Lisa Hammond et al.
Some eye health practitioners may hesitate to prescribe multifocal contact lenses due to the belief that the concomitant dysphotopsias are significant. In a clinical trial of 35 subjects, this research evaluates filtering HEV-lightŦ, as a design feature of multifocal contact lenses like the ACUVUE® OASYS MAX 1-Day multifocal contact lens, as a possible mechanism for reducing halos and light scatter.
Efficacy in Myopia Control: an Omnibus Model
Mark Bullimore et al.
Accurate prediction and monitoring of axial elongation and refractive progression are important for myopia management. This study is an update on progress in evidence-based interpretation of these features. The data showed that comparison to axial elongation charts provides the most sensitive means of monitoring progression. This omnibus model provides projections, and gives reference data, for efficacy of myopia control interventions based on 1-year data.
Cataract surgery disparities in the United States: How can optometry reduce the gap?
Tawnya Pastuck et al.
This compilation of 41 published literature on racial, ethnic and/or gender cataract care disparities along the continuum of care found four patient journey key points that impact cataract surgery outcomes: routine eye exam (affecting referrals), surgical evaluation, surgery, and post-operative care. The research showed that disparities along the care continuum impact cataract surgery outcomes for Black, Hispanic, Asian and female patients in the United States. Providers and healthcare systems have historically underutilized their unique power to expand beyond a strict biomedical role to better serve the community.
###
About Vision at Johnson & Johnson
Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients’ eyes. As a global leader in eye-health, we have a bold ambition: Vision Made Possible – and are paving the way for a new future of eye health to support the full spectrum of pediatric, developed and mature eyes.
Through cutting-edge innovation, scientific expertise, and advanced technologies, we are revolutionizing the way people see and experience the world. At every step of the eye health journey – from myopia solutions, contact lenses, refractive and cataract surgical solutions – to investigational gene therapies for retinal diseases, we stand as a trusted partner with the goal of making vision possible for customers and patients. Visit us at jjvision.com, follow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook.
Important Safety Information:
ACUVUE® Brand Contact Lenses are indicated for vision correction. As with any contact lens, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Lenses should not be prescribed if patients have any eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. Consult the package insert for complete information. Complete information is also available from Johnson & Johnson Vision Care, Inc. by calling 1-800-843-2020, or by visiting JNJVISIONPRO.com.
Ŧ Filtering of HEV light by contact lenses has not been demonstrated to confer any health benefit to the user, including but not limited to retinal protection, protection from cataract progression, reduced eye strain, improved contrast, improved acuity, reduced glare, improved low light vision, or improved circadian rhythm/sleep cycle. The Eye Care Professional should be consulted for more information.
* Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
+ Subjective Comfort Data has not been collected for ACUVUE® Abiliti® Overnight.
‡ Xiao-Yu Song is an employee of Johnson & Johnson.
1 JJV Data on File 2020. ACUVUE Brand - Eye-Inspired Innovations.
Third party trademarks are the property of their respective owners.
2024PP17460
